drugset / Trial / NCT02070380

Crossover Comparison of MultiHance and Dotarem

NCT02070380

Phase 4 Completed 179 enrolled Bracco Diagnostics, Inc
RandomizedCrossoverTriple-blindDiagnostic

Summary

This study aims at a comparison between MultiHance at a dose of 0.1 mmol/kg and 0.05 mmol/kg and Dotarem at a dose of 0.1 mmol/kg in brain tumor patients to show superiority of MultiHance.

Timeline

Start
2014-02
Primary completion
2015-03
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Gadobenate dimeglumine Diagnostic / imaging agent 0.05 mmol
Subject Gadobenate dimeglumine Diagnostic / imaging agent 0.1 mmol
Subject Gadoterate meglumine Diagnostic / imaging agent 0.1 mmol

Indications